AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
AAC Accepts, published online ahead of print on 14 May 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00209-07v1
51/8/2679    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meehl, M.
Right arrow Articles by Cheung, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meehl, M.
Right arrow Articles by Cheung, A.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00209-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Interaction of the GraRS Two-Component System with the VraFG ABC-Transporter to Support Vancomycin-Intermediate Resistance in Staphylococcus aureus

Michael Meehl, Silvia Herbert, Friedrich Götz, and Ambrose Cheung*

Department of Microbiology, Dartmouth Medical School, Hanover, NH, USA; Microbial Genetics, University of Tübingen, Tübingen, Germany

* To whom correspondence should be addressed. Email: Ambrose.Cheung{at}Dartmouth.edu.


   Abstract

Current treatment for serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) relies heavily upon the glycopeptide antibiotic vancomycin. Unfortunately, this practice has led to an intermediate resistance phenotype that is particularly difficult to treat in invasive staphylococcal diseases, such as septicemia and its metastatic complications, including endocarditis. Although the vancomycin intermediate resistance phenotype has been linked to abnormal cell wall structures and autolytic rates, the corresponding genetic changes have not been fully elucidated. Previously, whole-genome array studies listed numerous genes to be over-expressed in vancomycin intermediate sensitive strains including graRS (sacol0716-0717), encoding a two-component regulatory system, as well as the adjacent vraFG (sacol0718-0720), encoding an ATP-binding cassette (ABC) transporter; but the exact contribution of these genes to increased vancomycin resistance has not been defined. In this study, we showed that isogenic strains with mutations in genes encoding the GraRS TCRS and the VraFG ABC-transporter are hypersensitive to vancomycin as well as polymyxin B. Moreover, GraRS regulates the expression of the adjacent VraFG pump, reminiscent of Gram-positive bacteriocin-immunity regulons. Mutations of graRS and vraFG also led to increased autolytic rates and a more negative net surface charge, which may explain, in part, to their increased sensitivity to cationic antimicrobial peptides. Taken together, these data reveal an important genetic mediator to the VISA phenotype and may hold clues to the selective pressures on staphylococci upon exposure to selective cationic peptide antibiotics used in clinical practice.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.